Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis
Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Pirfenidone as anti-fibrosis drug developed in recent years demonstrated the potential anti- fibrotic effect, but so far there were no domestic studies about pirfenidone's efficacy and safety evaluation in china.
- Trial name
- IPF (NCT02136992)
- Testing
- Pirfenidone
- Volunteers
- 160 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Chronic Obstructive Pulmonary Disease, Asthma
Controls for Respiratory Diseases
This is the registry of control participants for patients with various respiratory diseases. We screened healthy volunteers who visited Seoul National Hospital Healthcare System Gangnam Center for routine health check-up, and…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis, Nontuberculous Mycobacterium Infection
- Trial name
- NCT03120481
- Testing
- no intervation
- Where
- South Korea
- Volunteers
- 1,572 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hypersensitivity Pneumonitis, Chronic Hypersensitivity Pneumonitis
Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis
The objective of this study is to administer and validate a disease specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP).
- Conditions
- Hypersensitivity Pneumonitis, Chronic Hypersensitivity Pneumonitis, Interstitial Lung Disease, Extrinsic Allergic Alveolitis
- Trial name
- CHP-HRQOL (NCT04273867)
- Testing
- Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Systemic Sclerosis, Scleroderma
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
By including in this study patients with significant worsening of their lung volumes and / or their DLCO (carbon monoxide diffusing capacity) in the previous year, on the basis of an open retrospective study we recently…
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Disease, Lung Fibrosis
- Trial name
- SCLEROCYC (NCT01570764)
- Testing
- Cyclophosphamide
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Failure, Long-term Non-invasive Ventilation
Ventilator-associated Injury (VAI) in Chronic Home Mechanical Ventilation
Rationale: The pathophysiological changes in respiratory muscle morphology and functioning in patients with end-stage pulmonary disease are not very well known.
- Trial name
- NCT04521426
- Testing
- No other than standard care
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Lung Diseases, Interstitial, NSCLC
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
The main goal of this prospective non-interventional exploratory study is to characterize the tumor micro-environment of advanced NSCLC in single-cell resolution, prior to immune checkpoint blockade exposure, and correlate the…
- Conditions
- Lung Diseases, Interstitial, NSCLC, Immunotherapy
- Trial name
- NCT04807114
- Testing
- Immune checkpoint inhibitor, Chemotherapy + Immune checkpoint inhibitor
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Idiopathic Pulmonary Fibrosis, Diffuse Parenchymal Lung Disease
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is an illness characterized by progressive decline in lung function and premature death from respiratory failure.
- Conditions
- Idiopathic Pulmonary Fibrosis, Diffuse Parenchymal Lung Disease, Interstitial Lung Disease
- Trial name
- NCT01462006
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Virginia
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
- Trial name
- NCT07407543
- Testing
- SRN001, 0.9% sodium chloride (normal saline)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- siRNAgen Therapeutics Inc.
Unresectable Locally Advanced Non-small Cell Lung Cancer
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
A prospective, single-center, phase II clinical study of adebrelimab combined with apatinib in the treatment of unresectable stage III NSCLC patients with grade ≤2 radiation pneumonitis after definitive chemoradiotherapy
- Trial name
- NCT06700421
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Zhou
Idiopathic Pulmonary Fibrosis
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis
The objective of the study is to assess the safety and tolerability of repeated doses of CHF10073 and to characterise cough-related safety outcomes associated with CHF10073 administration.
- Trial name
- NCT07876284
- Testing
- CHF10073 low dose, CHF10073 high dose
- Volunteers
- 18 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Interstitial Lung Disease Due to Systemic Disease
Registry of Autoimmune Interstitial Lung Disease
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma.
- Trial name
- EPIMAR (NCT05365009)
- Testing
- Multidisciplinary aproach
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- EPIMAR registry
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Lung Diseases, Interstitial, Exercise, Compulsive
Muscles Oxygenation During Exercise in Fibrosing Interstitial Lung Diseases
The type of this study is an observational prospective study. It will be done to determine the oxygenation status of the intercostal muscles and quadriceps femoris muscle during exercise in patients with fibrosing lung and to…
- Conditions
- Lung Diseases, Interstitial, Exercise, Compulsive, Oxygen Deficiency
- Trial name
- NCT05855447
- Testing
- NIRS device usage during 6MWT, Peripheral Muscle Strength Measurement, Pulmonary Function Test
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Saglik Bilimleri Universitesi
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Lung Neoplasm Malignant, Interstitial Lung Disease
Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
This is a prospective interventional open-label randomized trial. The patients treated with anti- PD-1 (programmed-death receptor type 1) or anti-PD-L1 (programmed-death ligand) antibodies in case of new acute onset interstitial…
- Trial name
- PROS-CONS (NCT04036721)
- Testing
- Prolonged glucocorticosteroid (prednisone) regimen, Short glucocorticosteroid (prednisone) regimen
- Where
- Poland
- Volunteers
- 85 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Idiopathic Pulmonary Fibrosis
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study was to investigate the safety, tolerability and efficacy of VAY736 as potential therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT03287414
- Testing
- VAY736, Standard of Care (SoC)
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Lung Diseases, Interstitial
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis…
- Trial name
- NCT05875532
- Where
- United States
- Volunteers
- 34,960 people
- Sponsor
- Boehringer Ingelheim
COPD (Chronic Obstructive Pulmonary Disease), Asthma (Diagnosis)
Validation of 1 Minute Sit-to Stand Test for Assessment of Breathlessness at Exertion in Individuals With Chronic Lung Disease
Breathlessness is a common symptom in people with chronic lung and heart diseases. It can affect daily activities, quality of life, and overall health.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Asthma (Diagnosis), Interstitial Lung Disease (ILD)
- Trial name
- V1BE (NCT07836764)
- Testing
- 1MSTS
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Jacob Sandberg
Pulmonary Fibrosis Idiopathic Familial
Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis
In this study the prognostic value of the current screening parameters for familial pulmonary fibrosis (FPF) will be investigated by looking at the screenings of 200 first-degree relatives of patients with FPF.
- Trial name
- FLORIS (NCT05367349)
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- St. Antonius Hospital
Vasculitis, Wegener's Granulomatosis
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
This study will evaluate the safety and effectiveness of a staged approach to therapy for Wegener's granulomatosis and other systemic vasculitides using prednisone plus cyclophosphamide followed by methotrexate.
- Trial name
- NCT00001473
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.